JPH0482830A - Skin drug for external use - Google Patents
Skin drug for external useInfo
- Publication number
- JPH0482830A JPH0482830A JP2193030A JP19303090A JPH0482830A JP H0482830 A JPH0482830 A JP H0482830A JP 2193030 A JP2193030 A JP 2193030A JP 19303090 A JP19303090 A JP 19303090A JP H0482830 A JPH0482830 A JP H0482830A
- Authority
- JP
- Japan
- Prior art keywords
- magnolia
- bark
- external use
- magnolol
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 5
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims abstract description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241000218378 Magnolia Species 0.000 claims abstract description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 claims abstract description 6
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 240000004580 Magnolia hypoleuca Species 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 241000218377 Magnoliaceae Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 4
- 206010000496 acne Diseases 0.000 abstract description 4
- 235000011105 Magnolia hypoleuca Nutrition 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 14
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は抗菌性に優れ且つ安全な皮膚外用剤に関する。[Detailed description of the invention] [Industrial application field] The present invention relates to a skin external preparation that has excellent antibacterial properties and is safe.
抗菌性を有する皮膚外用剤については、ザルファ剤、抗
生物質、各種の化学合成物質など、多種のものが知られ
ている。A wide variety of external skin preparations with antibacterial properties are known, including zulfa drugs, antibiotics, and various chemically synthesized substances.
しかし長期的な安全性については、必ずしも保証されて
いない。However, long-term safety is not necessarily guaranteed.
安全か保証され、更に抗菌性に優れた皮膚外用剤が求め
られている。There is a need for external skin preparations that are guaranteed to be safe and have excellent antibacterial properties.
一方、朴の木の樹皮の乾燥物である厚朴は局方記載の生
薬で鎮静、筋弛緩、抗けいれん、を髄反射抑制作用等が
あり、特にマグノロール、ホオノキオールは中枢性筋弛
緩作用が報告され、腹痛、かぜ等の病状に用いられてい
る。On the other hand, Koboku, which is the dried bark of the magnolia tree, is a medicinal herbal medicine listed in the pharmacopeia that has sedative, muscle relaxant, anticonvulsant, and spinal reflex suppressive effects, and in particular, magnolol and honokiol have been reported to have central muscle relaxant effects. It is used for medical conditions such as abdominal pain and colds.
しかし皮膚外用剤として、抗菌性を有することは報告さ
れていない。However, it has not been reported to have antibacterial properties as an external preparation for the skin.
本発明の目的は皮膚に対する長期的安全性が保証され、
しかも抗菌性に優れた皮膚外用剤を提供することである
。The purpose of the present invention is to ensure long-term safety for the skin,
Furthermore, it is an object of the present invention to provide a skin preparation with excellent antibacterial properties.
本発明者らは、永年にわたり生薬として使用されて来た
各種植物について、その抗菌性を鋭意研究した結果、朴
の木の樹皮に含まれるマグノロール、ホオノキオールに
ニキビに関係する菌を抑制する作用があることを見いだ
し、本発明を完成した。As a result of intensive research into the antibacterial properties of various plants that have been used as herbal medicines for many years, the present inventors found that magnolol and honokiol contained in the bark of the magnolia tree have the ability to inhibit acne-related bacteria. They discovered something and completed the present invention.
即ち本発明は
（１）マグノロール及び／又はホオノキオールを含む皮
膚外用剤であり、
（２）モクレン科ホオノキ属の樹皮を有機溶媒で抽出し
た液を含む皮膚外用剤であり、
（３）有機溶媒がメタノール、エタノール、エーテル、
アセトンよりなる群より選んだ少なくとも１種である前
記（２）記載の皮膚外用剤であり、（４）モクレン科ホ
オノキ属の樹皮が、朴木（ＭａｇｎｏＮａ ｏｂｏｖａ
ｔａ）である前記（２）記載の皮膚外用剤である。That is, the present invention is (1) a skin external preparation containing magnolol and/or honokiol, (2) a skin external preparation containing a liquid extracted with an organic solvent from the bark of the magnolia family Magnolia genus, and (3) an organic The solvent is methanol, ethanol, ether,
The skin external preparation according to (2) above, which is at least one selected from the group consisting of acetone, and (4) the bark of Magnolia magnolia in the Magnoliaceae family is
The skin external preparation according to (2) above, which is ta).
朴の木の樹皮の乾燥物である厚朴は神農本草経中品に収
載された古くから用いられてきた漢方薬であり、また局
方記載の原料でもあり、安全性に関してはなんら問題は
ない。Houboku, which is the dried bark of the magnolia tree, is a Chinese herbal medicine that has been used for a long time and is listed in the Shen-Nong Bencao Jing Chingong, and is also an ingredient listed in the pharmacopoeia, so there are no safety issues.
しかしながら、該厚朴は、もっばら経口より用いられ、
腹痛、かぜ等の病状に用いられているにすぎない。However, Koboku is mostly used orally,
It is only used for medical conditions such as abdominal pain and colds.
モクレン科ホオノキ属の樹皮から、有効成分を抽出する
には、抽出方法には種々あるが、有機溶媒、特にメタノ
ール、エタノール、エーテル、アセトンより選んた少な
くとも１種の溶媒を用いて抽出する方法が有効である。There are various extraction methods for extracting the active ingredients from the bark of the Magnolia genus, Magnoliaceae, but the best method is to use an organic solvent, especially at least one solvent selected from methanol, ethanol, ether, and acetone. It is valid.
抽出物から、マグノロールまたはホウツキオールまで単
離する必要はなく、これらの物質が含有されている状態
であればかまわない。It is not necessary to isolate magnolol or boutsukiol from the extract; it is sufficient that these substances are contained.
マグノロールとホオノキオールの化学構造はマグノロー
ル、ホオノキオール、ホオノキのメタノール抽出物（乾
燥物）について、抗菌性を調べるため、下記の細菌につ
いて、最小発育阻止濃度（ＭＩＣ）を測定した。Regarding the chemical structures of Magnolol and Hoonokiol, in order to investigate the antibacterial properties of Magnolol, Hoonokiol, and a methanol extract (dry product) of Magnolia, the minimum inhibitory concentration (MIC) was measured for the following bacteria.
方法としては液体培養法を用いた。液体培養法では検体
が分散状態のものは、培養時、振とうを加えた。A liquid culture method was used as the method. When using the liquid culture method, if the specimen was in a dispersed state, shaking was added during culture.
その結果を第１表に示す。The results are shown in Table 1.
第 １ 表 （単位 ｐｐｍ）
この結果から、これらの物質が何れも毛嚢内細菌に有効
であることが分かった。Table 1 (unit: ppm) From the results, it was found that all of these substances were effective against bacteria within the hair follicle.
本発明を実施例により、更に具体的に説明するが、本発
明はこの実施例によって何等限定されるものではない。The present invention will be explained in more detail with reference to Examples, but the present invention is not limited to these Examples in any way.
（実施例１）
皮膚外用剤
エタノール １０重量％１．３ブチレ
ングリコール ４重量％マグノロール
１重量％水 ８５重量
％（実施例２）
実施例１のマグノロールをホオノキオールに置き換えた
皮膚外用剤。(Example 1) Skin external preparation Ethanol 10% by weight 1.3 butylene glycol 4% by weight Magnolol
1% by weight water 85% by weight (Example 2) A skin external preparation in which magnolol in Example 1 was replaced with hoonokiol.
（実施例３）
実施例］のマグノロールをホオノキのメタノール抽出液
（乾燥物）に置き換えた皮膚外用剤。(Example 3) A skin external preparation in which Magnolol in Example] was replaced with a methanol extract (dry product) of Magnolia magna.
（比較例１） 実施例１のマグノロールを水に置き換えたもの。(Comparative example 1) Magnolol in Example 1 was replaced with water.
（評価方法） 二重盲検法を用いて、女性１６名で実験した。(Evaluation method) The experiment was conducted on 16 women using a double-blind method.
各検体８名づつで顔面を左右に分けて行った。The face was divided into left and right sides for each sample of 8 people.
実施期間は２ケ月間行った。結果を第２表に示す。The implementation period was two months. The results are shown in Table 2.
第２表
〔発明の効果〕
モクレン科ホオノキ属の樹皮のメタノール、エタノール
、エーテル、アセトン等の溶媒の少なくとも１種を使用
して抽出した液又はこの抽出液中の有効成分であるマグ
ノロールまたはホオノキオールを含む皮膚外用剤はニキ
ビに著効があることがわかった。Table 2 [Effects of the Invention] A liquid extracted from the bark of the genus Magnolia of the Magnoliaceae family using at least one solvent such as methanol, ethanol, ether, acetone, etc., or an active ingredient in this extract, Magnolol or Magnolia It was found that a topical skin preparation containing all is highly effective against acne.
Claims (1)
外用剤。 ２、モクレン科ホオノキ属の樹皮を有機溶媒で抽出した
液を含む皮膚外用剤。 ３、有機溶媒がメタノール、エタノール、エーテル、ア
セトンよりなる群より選んだ少なくとも１種である請求
項２記載の皮膚外用剤。 ４、モクレン科ホオノキ属の樹皮が、朴木 （Ｍａｇｎｏｌｉａ ｏｂｏｖａｔａ）である請求項２
記載の皮膚外用剤。[Scope of Claims] 1. A skin external preparation containing magnolol and/or honokiol. 2. A skin external preparation containing a liquid extracted from the bark of the Magnolia genus Magnoliaceae with an organic solvent. 3. The skin external preparation according to claim 2, wherein the organic solvent is at least one selected from the group consisting of methanol, ethanol, ether, and acetone. 4. Claim 2, wherein the bark of Magnolia genus Magnoliaceae is Magnolia obovata.
External skin preparations listed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2193030A JP2746737B2 (en) | 1990-07-23 | 1990-07-23 | External preparation for acne skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2193030A JP2746737B2 (en) | 1990-07-23 | 1990-07-23 | External preparation for acne skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0482830A true JPH0482830A (en) | 1992-03-16 |
| JP2746737B2 JP2746737B2 (en) | 1998-05-06 |
Family
ID=16301001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2193030A Expired - Fee Related JP2746737B2 (en) | 1990-07-23 | 1990-07-23 | External preparation for acne skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2746737B2 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003086432A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic lotion for dermatitis |
| WO2003086433A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic cream for dermatitis |
| KR100699538B1 (en) * | 2005-09-14 | 2007-03-23 | 바이오스펙트럼 주식회사 | Composition for improving atopic dermatitis comprising magnolol and honokiol |
| FR2911507A1 (en) * | 2007-01-19 | 2008-07-25 | Europ Finances | Use of lignans and-or neolignans in pharmaceutical, cosmetic, dermatological or neutraceutic compositions for the inhibition of aromatase or SHBG, e.g. for the treatment of conditions such as acne or alopecia |
| JP2008542361A (en) * | 2005-05-30 | 2008-11-27 | コリア インスティテュート オブ オリエンタル メディシン | Mass separation of magnolol from magnolia cortex or magnolia root |
| KR100971269B1 (en) * | 2008-02-15 | 2010-07-20 | 주식회사 유니젠 | Processed magnolia extract and anti-microbial composition comprising the same |
| KR101006342B1 (en) * | 2008-06-30 | 2011-01-10 | 주식회사 코리아나화장품 | Cosmetic Composition for Protecting the Skin Comprising the Extract of Magnolia Sieboldii |
| WO2011038797A1 (en) * | 2009-10-02 | 2011-04-07 | Beiersdorf Ag | Use of magnolol or honokiol as antibacterial, antimycotic, antiparasitic, or antiviral active ingredients |
| CN102743363A (en) * | 2011-04-20 | 2012-10-24 | 上海莱博生物科技有限公司 | Product for treating skin diseases caused by Malassezia |
| CN102871989A (en) * | 2011-07-04 | 2013-01-16 | 四川大学 | External preparation containing either honokiol or pharmaceutically acceptable salt of honokiol and new application |
-
1990
- 1990-07-23 JP JP2193030A patent/JP2746737B2/en not_active Expired - Fee Related
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003086433A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic cream for dermatitis |
| JPWO2003086432A1 (en) * | 2002-04-15 | 2005-08-18 | 哲夫 山東 | Dermatitis lotion |
| JPWO2003086433A1 (en) * | 2002-04-15 | 2005-08-18 | 哲夫 山東 | Dermatitis treatment cream |
| WO2003086432A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic lotion for dermatitis |
| US7572469B2 (en) | 2002-04-15 | 2009-08-11 | Tetsuo Santo | Therapeutic lotion for dermatitis |
| JP2008542361A (en) * | 2005-05-30 | 2008-11-27 | コリア インスティテュート オブ オリエンタル メディシン | Mass separation of magnolol from magnolia cortex or magnolia root |
| JP4757911B2 (en) * | 2005-05-30 | 2011-08-24 | コリア インスティテュート オブ オリエンタル メディシン | Mass separation of magnolol from magnolia cortex or magnolia root |
| KR100699538B1 (en) * | 2005-09-14 | 2007-03-23 | 바이오스펙트럼 주식회사 | Composition for improving atopic dermatitis comprising magnolol and honokiol |
| WO2008102086A3 (en) * | 2007-01-19 | 2008-10-09 | Europ Finances | Use of compositions containing at least one lignane and/or neolignane for modulating testosterone levels |
| FR2911507A1 (en) * | 2007-01-19 | 2008-07-25 | Europ Finances | Use of lignans and-or neolignans in pharmaceutical, cosmetic, dermatological or neutraceutic compositions for the inhibition of aromatase or SHBG, e.g. for the treatment of conditions such as acne or alopecia |
| KR100971269B1 (en) * | 2008-02-15 | 2010-07-20 | 주식회사 유니젠 | Processed magnolia extract and anti-microbial composition comprising the same |
| KR101006342B1 (en) * | 2008-06-30 | 2011-01-10 | 주식회사 코리아나화장품 | Cosmetic Composition for Protecting the Skin Comprising the Extract of Magnolia Sieboldii |
| WO2011038797A1 (en) * | 2009-10-02 | 2011-04-07 | Beiersdorf Ag | Use of magnolol or honokiol as antibacterial, antimycotic, antiparasitic, or antiviral active ingredients |
| DE102009048044A1 (en) * | 2009-10-02 | 2011-04-21 | Beiersdorf Ag | Use of magnolol or honokiol as antibacterial, antimycotic, antiparasitic or antiviral agents |
| CN102743363A (en) * | 2011-04-20 | 2012-10-24 | 上海莱博生物科技有限公司 | Product for treating skin diseases caused by Malassezia |
| CN102871989A (en) * | 2011-07-04 | 2013-01-16 | 四川大学 | External preparation containing either honokiol or pharmaceutically acceptable salt of honokiol and new application |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2746737B2 (en) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2554766C2 (en) | Compositions, containing anti-inflammatory mixture | |
| KR100417791B1 (en) | Antibiotic and cosmetic compositions containing herb medicines | |
| Meguellati et al. | Evaluation of acute, subacute oral toxicity and wound healing activity of mother plant and callus of Teucrium polium L. subsp. geyrii Maire from Algeria | |
| CN110035797B (en) | Synergistic herbal composition with prebiotic properties for the treatment of acne | |
| US11826393B2 (en) | Ointment-based skin wound treatment method | |
| CN102961282B (en) | Composition with penetration enhancing effect as well as preparation method and application thereof | |
| KR100780666B1 (en) | An extract from Dryopteris crassirhizoma for prevention and remedy of an acne and a composition of cosmetic including the extract | |
| JP2693859B2 (en) | Acne vulgaris skin external preparation for acne | |
| JPH0482830A (en) | Skin drug for external use | |
| CN106177100B (en) | Composition with acne removing effect and application thereof | |
| JPH0482814A (en) | Beautifying cosmetic | |
| CN113274331A (en) | Acne-removing and anti-inflammatory composition and preparation method and application thereof | |
| Sheth et al. | Pityriasis capitis: Causes, pathophysiology, current modalities, and future approach | |
| KR20030011731A (en) | Antibiotic and cosmetic compositions containing herb medicines | |
| JPH0987188A (en) | Skin preparation for external use and bathing agent | |
| Gerber et al. | Stability, clinical efficacy, and antioxidant properties of Honeybush extracts in semi-solid formulations | |
| Barku et al. | In-vitro Antioxidant and Wound Healing Properties of Combretum dolichopetalum Engl. & Diels (Combretaceae | |
| CN113244148A (en) | A skin care composition | |
| Thaher | A Natural Anthraquinone Plants with Multi-Pharmacological Activities | |
| JP2894715B2 (en) | External preparation for skin | |
| JP5972732B2 (en) | Antibacterial agent and external preparation for skin | |
| JP6723979B2 (en) | Wrinkle improver | |
| JP2000169328A (en) | Epidermal permeation barrier enhancer and skin cosmetic | |
| KR930004934B1 (en) | Morus alba extracts for acne | |
| JP4666937B2 (en) | Antibacterial agent derived from herbal medicine and composition for external use containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |